



## Design, synthesis, nuclear localization, and biological activity of a fluorescent duocarmycin analog, HxTfA

Kostantinos Kiakos<sup>a,b,c,\*</sup>, Bernhard Englinger<sup>f</sup>, Stephanie K. Yanow<sup>d</sup>, Debora Wernitznig<sup>b,c</sup>, Michael A. Jakupec<sup>b,c</sup>, Walter Berger<sup>c,f</sup>, Bernhard K. Keppler<sup>b,c</sup>, John A. Hartley<sup>a</sup>, Moses Lee<sup>e,1</sup>, Pravin C. Patil<sup>e</sup>

<sup>a</sup> Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, London WC1E 6BT, United Kingdom

<sup>b</sup> Institute of Inorganic Chemistry, University of Vienna, Waehringer Str. 42, 1090 Vienna, Austria

<sup>c</sup> Research Cluster "Translational Cancer Therapy Research", University of Vienna, Waehringer Str. 42, 1090 Vienna, Austria

<sup>d</sup> School of Public Health, University of Alberta, Edmonton, Canada

<sup>e</sup> Department of Chemistry, Hope College, Holland, MI 49423, United States

<sup>f</sup> Institute of Cancer Research and Comprehensive Cancer Center, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria

### ARTICLE INFO

#### Article history:

Received 20 November 2017

Revised 23 February 2018

Accepted 5 March 2018

Available online 5 March 2018

#### Keywords:

Duocarmycins

Tafuramycin A

Cytotoxic

Antimalarial

Vaccine

Minor groove

Adenine-N3

Alkylating agent

### ABSTRACT

HxTfA **4** is a fluorescent analog of a potent cytotoxic and antimalarial agent, TfA **3**, which is currently being investigated for the development of an antimalarial vaccine, PlasProtect<sup>®</sup>. HxTfA contains a p-anisylbenzimidazole or Hx moiety, which is endowed with a blue emission upon excitation at 318 nm; thus enabling it to be used as a surrogate for probing the cellular fate of TfA using confocal microscopy, and addressing the question of nuclear localization. HxTfA exhibits similar selectivity to TfA for A-tract sequences of DNA, alkylating adenine-N3, albeit at 10-fold higher concentrations. It also possesses in vitro cytotoxicity against A549 human lung carcinoma cells and *Plasmodium falciparum*. Confocal microscopy studies showed for the first time that HxTfA, and by inference TfA, entered A549 cells and localized in the nucleus to exert its biological activity. At biologically relevant concentrations, HxTfA elicits its DNA damage response as evidenced by a marked increase in the levels of  $\gamma$ H2AX observed by confocal microscopy and immunoblotting studies, and ultimately induces apoptosis.

© 2018 Elsevier Ltd. All rights reserved.


Duocarmycin SA **1** (Fig. 1),<sup>1</sup> yatakemycin,<sup>2</sup> and CC-1065<sup>3</sup> are the parent members of a potent class of antitumor natural products that contain two components: the cyclopyrrolindolone (CPI) DNA alkylating moiety and a non-covalently active portion, such as the 5,6,7-trimethoxyindole (TMI). The crescent-shaped molecules fit snugly in the minor groove of AT-rich sequences of DNA. Upon binding, the reactivity of the cyclopropane moiety, as in **1**, is enhanced for covalent bonding with adenine-N3,<sup>4</sup> leading to the killing of cancer cells through apoptosis.<sup>5</sup> Due to clinical toxicity observed with the initial group of CC-1065 and duocarmycin analogs, such as adozelesin, bizelesin, carzelesin, and KW2189, a major effort has been underway for over two decades to develop analogs that are more targeted, more selectively active, and less

systemically toxic.<sup>6</sup> As a result, numerous duocarmycin analogs have been developed. Examples include: *seco*-cyclopropylbenzoin-doline-TMI (**2**, Fig. 1), a stable, sequence specific, and highly cytotoxic agent<sup>7</sup>; centanamycin, (achiral *seco*-amino-CBI-TMI),<sup>8</sup> an orally active anticancer agent against human cancer xenografts<sup>9</sup>; and *seco*-iso-cyclopropylfuranoidindoline-trimethoxyindole (*seco*-iso-CFI-TMI or tafuramycin A or TfA **3**),<sup>10</sup> a potent cytotoxic agent against cancer cells. Recently, both centanamycin<sup>11</sup> and TfA<sup>12</sup> were reported to exhibit potent cytotoxic activity against *Plasmodium falciparum*. *Seco*-compounds, such as **2** and **3**, Fig. 1, eliminate HCl in cells to form the ultimate cyclopropane drugs, e.g., **3a**, which bind and covalently bond with adenine-N3 on DNA. TfA is a critical component in the development of the antimalarial vaccine, PlasProtect<sup>®</sup>, which is currently being tested clinically.<sup>12</sup> Another duocarmycin analog, DUBA, is currently undergoing clinical evaluation and is part of a HER2-targeting antibody-drug conjugate SYD985, which is being developed clinically for HER2-expressing breast cancers.<sup>13</sup>


\* Corresponding author at: Institute of Inorganic Chemistry, University of Vienna, Waehringer Str. 42, 1090 Vienna, Austria.

E-mail address: [konstantinos.kiakos@univie.ac.at](mailto:konstantinos.kiakos@univie.ac.at) (K. Kiakos).

<sup>1</sup> Present address: Department of Chemistry, Georgia State University, Atlanta, GA 30303, United States.




**Fig. 1.** Structure of duocarmycin SA **1**; *seco*-CBI-TMI **2**; *seco*-iso-CFI-TMI or tafuramycin A or TfA **3**; **3a** is the putative active cyclopropane drug of tafuramycin A, and its reaction with adenine-N3; and *seco*-iso-CFI-Hx or HxTfA **4**.



**Fig. 2.** Synthesis of HxTfA **4**.

Despite the major progress made so far in the duocarmycins and CC-1065 field for the development of novel anticancer and antiparasitic agents, one important question that needs to be answered is evidence of nuclear localization of these compounds. Since duocarmycins have been shown to bind and alkylate naked and genomic DNA extracted from cells,<sup>1,8b,14</sup> it is often assumed that these compounds interact with nuclear DNA. Recently, Tietze's group reported the design and synthesis of a number of coumarin-based, fluorescent duocarmycin analogs for the purpose of studying the molecular fate of the compounds in live cancer cells using confocal microscopy.<sup>15</sup> Even though the compounds displayed strong cytotoxicity against the growth of cancer cells, surprisingly, they penetrated the cellular membrane and accumulated in the mitochondria, inducing apoptosis. Another effort led by Tercel's group involved the development of terminal-alkyne-containing duocarmycin analogs; upon binding to DNA, the alkyne moiety could be "clicked" with a reporter fluorophore-azide to determine nucleus localization.<sup>16</sup> The authors cautioned that "care must be exercised in interpreting sites of intracellular probe molecule localization on the basis of a click fluorescent read-out, especially where multiple diverse targets are possible, and even more so when some of these targets may be within the nucleus."<sup>16</sup> Since our group has been actively developing inherently fluorescent, DNA sequence selective, Hx-containing pyrrole-imidazole polyamides, or Hx-amides,<sup>17</sup> we envisioned that the Hx-moiety would be an appropriate replacement of the TMI unit in duocarmycins. Hx would retain the AT sequence and minor groove selectivity, and provide an anchor needed to "twist" and activate the cyclopropane toward nucleophilic reaction with adenine-N3. It would also come with the added benefit of the inherent fluorescent property afforded by the Hx moiety. Accordingly, we report herein



**Fig. 3.** Autoradiogram of a thermal cleavage gel showing purine-N3 lesions on the bottom strand of a 5'-<sup>32</sup>P-labeled 208-bp fragment of pUC18. G + A lane; 0, control; TfA **3**: 0.1, 0.3, 1, 3, 10, and 30 μM; and HxTfA **4**: 0.1, 0.3, 1, 3, 10, and 30 μM.


the synthesis of *seco*-iso-CFI-Hx or HxTfA **4** as a fluorescent surrogate of TfA **3**.

The synthesis of HxTfA is illustrated in Fig. 2. Acid catalyzed removal of the BOC protecting group of O-benzylated iso-CFI compound **5**<sup>18</sup> provided an indoline intermediate, which was coupled to Hx-acid **6**<sup>19</sup> in the presence of EDCI. The resulting amide **7** was isolated as a white solid in 59% yield after silica gel column chromatography. Hydrogenolysis of amide **7** with 10% Pd on carbon, at room temperature and atmospheric pressure, generated HxTfA in 33% yield as a white solid, after purification by silica gel column chromatography.<sup>20</sup> A 12.5  $\mu$ M solution of HxTfA in 1:1 water:DMSO gave an absorbance at about 320 nm, and excitation at 318 nm produced a blue emission at 370 nm.

The in vitro cytotoxicity of HxTfA and TfA, against A549 human lung carcinoma cells<sup>8,17c</sup> and *Plasmodium falciparum*<sup>11a,21</sup> was determined following published procedures. The IC<sub>50</sub> values (concentrations required to inhibit the growth of cells by 50%) of HxTfA and TfA following a 4-day continuous exposure for A549, and a 48 h exposure for *Plasmodium falciparum* 3D7 infected red blood cells, were 26 nM and 3.7 nM, and 3.7 nM and 64 pM, respectively. The results established that HxTfA was about 7-fold less cytotoxic than TfA in A549 cells, and about 60-fold less active than TfA against *Plasmodium*. Although the reasons for the

difference in cytotoxicities are unknown, one possible explanation is the 10-fold lower DNA reactivity of HxTfA compared to TfA. Interestingly, TfA is generally more cytotoxic against A549 cells than murine cancer cells: L1210 (lymphoma, IC<sub>50</sub> = 53 nM) and B16 (melanoma, IC<sub>50</sub> = 40 nM), as reported earlier.<sup>10</sup> With regard to antimalarial activity, TfA, with an IC<sub>50</sub> value of 64 pM, is one of the most potent cytotoxic agents against *Plasmodium falciparum* (about 30 times more potent than centanamycin),<sup>11a,22</sup> and comprises a critical ingredient for creating the chemically attenuated blood-stage parasite-based vaccine, PlasProtect<sup>®</sup>, for targeting human *Plasmodium* species.<sup>12</sup>

The DNA binding properties of HxTfA and TfA were ascertained using the thermal cleavage assay.<sup>8,10a,10b</sup> The 749–956 region of the pUC18 plasmid used to probe the purine-N3 alkylations, containing the prominent sites of damage on the bottom strand, was PCR amplified, using the synthetic primer 5'-CTCACTCAAAGGCGG-TAATAC-3', and the radiolabelled 5'-TGGTATCTTTATAGTCCTGTCG-3'. The resulting singly end-labeled fragment was generated, purified, and incubated with HxTfA and TfA for 5 h. The precipitated pellets from the drug-DNA incubations were re-suspended in sodium citrate buffer (pH 7.2) and heated at 90 °C for 30 min, to thermally cleave at the sites of adenine- or guanine-N3 lesions.<sup>8,10a,10b</sup> As shown in Fig. 3, both compounds share similar



**Fig. 4.** (A) Visualization of HxTfA **4** nuclear uptake. A549 cells were treated with the indicated concentrations of HxTfA (0, control; 0.5, 1.0, and 5.0  $\mu$ M) for 24 h, washed with PBS, and fixed with 2% paraformaldehyde (PFA). They were subsequently permeabilized and the nuclei were stained with propidium iodide (PI) before confocal microscopy imaging. The composite image presents the superimposed overlay of HxTfA fluorescence and the PI fluorescence. No HxTfA fluorescent signal was detected in the control, untreated cells under the same observation settings. (B) Fluorescence microscopy of A549 cells treated overnight with 50 and 100  $\mu$ M HxTfA, with the corresponding controls. Non-fixed, non-permeabilised cells were counterstained with the fluorescent MitoTracker dye (150 nM), which selectively stains active mitochondria in live cells, and were immediately observed by microscopy. The composite image presents the superimposed HxTfA fluorescence and the Mitotracker fluorescence.





Fig. 4 (continued)

DNA sequence selectivity by covalently interacting with the same cluster of adenines as their predominant site of DNA interaction, alkylating the N3 position of 5'-AAAAA-3' (865), while a secondary cleavage product is also evident at the AT-mixed sequence 5'-TTTTA-3' (843) for HxTfA. TfA appears therefore to be more DNA sequence selective and about 10-fold more reactive with DNA, than HxTfA, as judged by the appearance of the cleavage band at the major alkylation site **A**(865) at 0.1  $\mu\text{M}$ , compared to 1  $\mu\text{M}$  for HxTfA, which could also explain the higher cytotoxicity of TfA over HxTfA.

Exploiting the fluorescent properties of HxTfA **4**, and following published procedures,<sup>17</sup> confocal microscopy studies were conducted to determine the compound's cellular uptake. A549 cells were treated with increasing concentrations of HxTfA (0, 0.5, 1.0, and 5.0  $\mu\text{M}$ ) for 24 h and representative confocal microscopy images are shown in Fig. 4A. Nuclear accumulation was confirmed by co-localization of the HxTfA fluorescence signal (blue) and the propidium iodide (PI) signal (red). HxTfA nuclear staining was evident at 1.0  $\mu\text{M}$ , thus providing unambiguous evidence that HxTfA localizes in the nucleus. Fluorescence microscopy experiments in non-fixed, non-permeabilised A549 cells, treated with HxTfA for

24 h and counterstained with Mitotracker®Red CMXRos, further corroborated the HxTfA nuclear uptake (Fig. 4B).

Finally, to ascertain the mechanism of cytotoxicity of HxTfA, immunoblotting experiments (Fig. 5A) revealed that exposure of A549 cells to HxTfA (0.1–20  $\mu\text{M}$ ) for 5 h followed by 24 h of recovery caused a marked decrease in the levels of survivin (an anti-apoptotic protein) at concentrations 1  $\mu\text{M}$  and higher. Consistent with our previous observations, TfA produced the same effect at a 10-fold lower concentration (0.1  $\mu\text{M}$ ). Bcl-xL levels remained largely unaffected. Apoptosis was confirmed by the immunodetection of cleaved caspase-3, upon treatment with 1.0  $\mu\text{M}$  HxTfA (Fig. 5B). Furthermore, increased levels of  $\gamma$ -H2AX, a biomarker for DNA damage response was evident at 0.1  $\mu\text{M}$  and became more pronounced at higher drug concentrations. The induction of  $\gamma$ -H2AX was also detected by immunofluorescence, in cells treated with both TfA and HxTfA for 5 h and allowed to recover in drug-free medium for a further 24 h. Indicative confocal microscopy images shown in Fig. 5C revealed that both TfA and HxTfA produce significant nuclear  $\gamma$ -H2AX staining, relative to the untreated cells, with a lower TfA concentration required, consistent with its higher DNA reactivity and cytotoxicity, over HxTfA.



**Fig. 5.** Effects of TFA **3** and HxTfA **4**, on cellular apoptosis-related proteins and on DNA damage response. A549 cells were pre-treated with the indicated concentrations of TFA **3** and HxTfA **4** for 5 h. After 24 h in drug free medium, the cells were analysed by immunoblotting and confocal microscopy. (A) Results from immunoblotting experiments, detecting the levels of survivin and bcl-xL in treated and control A549 cells. (B) Immunodetection of the levels of cleaved caspase-3 and γ-H2AX in treated and control cells. (C) Confocal microscopy images of γ-H2AX foci in treated and control cells.

In summary, HxTfA has been shown to readily enter cells, localize in the nucleus, affect cellular processes, and induce apoptosis. Its biological profile is consistent and similar to that of TfA or

tafuramycin A, a valuable duocarmycin analog for the development of an antimalarial vaccine. The results support the notion that HxTfA can act as an appropriate surrogate for TfA, for cell studies.

## Acknowledgements

The authors thank the NSF (CHE 0809162) and Cancer Research UK (C2259/A16569). The research leading to these results has received funding from the Mahlke-Obermann Stiftung and the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 609431.

## A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.bmcl.2018.03.016>.

## References

- (a) Boger DL, Johnson DS. *Angew Chem Int Ed Engl*. 1996;35:1438;  
(b) Boger DL. *Acc Chem Res*. 1995;28:20;  
(c) Boger DL, Johnson DS. *Proc Natl Acad Sci USA*. 1995;92:3642;  
(d) Boger DL, Garbaccio RM. *Acc Chem Res*. 1999;32:1043;  
(e) Tichenor MS, Boger DL. *Nat Prod Rep*. 2008;25:220;  
(f) Ghosh N, Sheldrake HM, Searcey M, Pors K. *Curr Top Med Chem*. 2009;9:1494.
- Ichimura M, Ogawa T, Takahashi K, Kobayashi E, Kawamoto I, Yasuzawa T, Takahashi I, Nakano H. *J Antibiot*. 1990;43:1037.
- (a) Igarashi Y, Futamata K, Fujita T, Sekine A, Senda H, Naoki H, Furumai T. *J Antibiot*. 2003;56:107. Structure revision;  
(b) Tichenor MS, Kastrinsky DB, Boger DL. *J Am Chem Soc*. 2004;126:8396.
- Martin DG, Biles C, Gerpheide SA, et al. *J Antibiot*. 1981;34:1119.
- (a) Wrasidlo W, Johnson DS, Boger DL. *Bioorg Med Chem Lett*. 1994;4:631;  
(b) Wang Y, Yuan H, Ye W, Wright SC, Wang H, Larrick JW. *J Med Chem*. 2000;43:1541.
- Patil PC, Satam V, Lee M. *Anticancer Agents Med Chem*. 2015;15:616.
- (a) Boger DL, McKie JA. *J Org Chem*. 1995;60:1271;  
(b) Boger DL, Yun W, Han N. *Bioorg Med Chem*. 1995;3:1429.
- (a) Sato A, McNulty L, Cox K, et al. *J Med Chem*. 2005;48:3903;  
(b) Kiakos K, Sato A, Asao T, McHugh PJ, Lee M, Hartley JA. *Mol Cancer Ther*. 2007;6:2708.
- Rayburn E, Wang W, Li M, et al. *Cancer Chemother Pharmacol*. 2012;69:1423.
- (a) Howard TT, Lingerfelt BM, Purnell BL, et al. *Bioorg Med Chem*. 2002;10:2941;  
(b) Purnell B, Lingerfelt B, Scott A, et al. *Med Chem*. 2006;2:139;  
(c) Patil PC, Lee M. *Tetrahedron Lett*. 2014;55:3283;  
(d) El-Deeb IM, Rose FJ, Healy PC, von Itzstein M. *Org Biomol Chem*. 2014;12:4260.
- (a) Yanow SK, Purcell LA, Pradel G, et al. *J Infect Dis*. 2008;197:527;  
(b) Purcell LA, Wong KA, Yanow SK, Lee M, Spithill TW, Rodriguez A. *Vaccine*. 2008;26:4880.
- (a) Good MF, Reiman JM, Rodriguez IB, et al. *J Clin Invest*. 2013;123:3353;  
(b) Stanisic DI, Good MF. *Vaccine*. 2015;33:7469;  
(c) Good M, Reiman J, McPhun V, et al. *J Immunol*. 2013;190:1;  
(d) Reiman J, McPhun V, Ito K, Lee M, Good M. *J Immunol*. 2013;190:2.
- (a) Black J, Menderes G, Bellone S, et al. *Mol Cancer Ther*. 1900;2016:15;  
(b) Elgersma RC, Coumans RG, Huijbregts T, et al. *Mol Pharm*. 2015;12:1813.
- Kiakos K, Howard TT, Lee M, Hartley JA, McHugh PJ. *J Biol Chem*. 2002;277:44576.
- (a) Tietze LF, Behrendt F, Pestel GF, Schubert I, Mitkovski M. *Chem Biodivers*. 2012;9:2559;  
(b) Tietze LF, Behrendt F, Major F, Krewer B, von Hof JM. *Eur J Org Chem*. 2010;2010:6909.
- Tercel M, McManaway SP, Liyanage HD, Pruijn FB. *ChemMedChem*. 2014;9:2193.
- (a) Pett L, Kiakos K, Satam V, et al. *Biochim Biophys Acta*. 2017;1860:617;  
(b) Satam V, Babu B, Patil P, et al. *Bioorg Med Chem Lett*. 2015;25:3681;  
(c) Kiakos K, Pett L, Satam V, et al. *Chem Biol*. 2015;22:862;  
(d) Satam V, Patil P, Babu B, et al. *Bioorg Med Chem Lett*. 2013;23:1699;  
(e) Chavda S, Liu Y, Babu B, et al. *Biochemistry*. 2011;50:3127.
- Patil P, Cousins K, Smith M, et al. *Tetrahedron Lett*. 2013;54:4756.
- Satam VS, Patil PC, Babu B, et al. *Bulg Chem Commun*. 2016;48:725.
- Synthesis of 1-(chloromethyl)-5-hydroxy-1,2-dihydro-3-[(p-anisylbenzimidazole-2-carbonyl)-3H-furano[2,3-e]indoline, HxTfA 4: A solution of compound 7 (200 mg, 0.36 mmol) in THF (25 mL), MeOH (5.0 mL), and 10% Pd/C (100 mg) was hydrogenated at room temperature and atmospheric pressure for three days at room temperature. Removal of the catalyst and purification by silica gel column chromatography (7:3 ethyl acetate:hexanes) gave HxTfA 4 (55 mg, 0.12 mmol) in 33% yield as a white solid. Melting point: 210–213 °C (dec); R<sub>f</sub> 0.30 (3:1 ethyl acetate:hexanes); IR (ATR) 3307, 2961, 2923, 2851, 1614, 1593, 1494, 1446, 1414, 1379, 1334, 1258, 1175, 1087, 1015, 862 cm<sup>-1</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.07 (d, J = 8.0 Hz, 2H), 7.84 (s br, 1H), 7.72 (s br, 2H), 7.62 (s, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.12 (d, J = 8.0 Hz, 2H), 6.86 (s, 1H), 4.41 (dd, J = 8.0 Hz, 12.0 Hz, 1H), 4.23 (m, 1H), 4.04 (m, 2H), 3.90 (s, 3H), 3.86 (t, J = 8.0 Hz, 1H); LRMS (TOF-MS-ES<sup>+</sup>) 474 (M+H<sup>+</sup>, 100%); HRMS (M+H<sup>+</sup>) calcd. m/z for C<sub>26</sub>H<sub>21</sub>ClN<sub>3</sub>O<sub>4</sub> 474.1221, found 474.1223.
- Chavda S, Babu B, Yanow SK, et al. *Bioorg Med Chem*. 2010;18:5016.
- (a) Travassos M, Laufer MK. In: Daily J, Baron EL. (eds.). UpToDate, Waltham, MA (Accessed on January 8, 2017);  
(b) Mishra M, Mishra VK, Kashaw V, Iyer AK, Kashaw SK. *Eur J Med Chem*. 2017;125:130.